{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:58Z","timestamp":1784347438099,"version":"3.55.0"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.2169\/internalmedicine.5163-24","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:08:05Z","timestamp":1765404485000},"page":"1979-1984","source":"Crossref","is-referenced-by-count":1,"title":["New-onset Anti-melanoma Differentiation-associated Gene 5 Antibody Positive Clinically Amyopathic Dermatomyositis Following COVID-19"],"prefix":"10.2169","volume":"65","author":[{"given":"Yu","family":"Nakanishi","sequence":"first","affiliation":[{"name":"Department of Respiratory Internal Medicine, Hiroshima City North Medical Center Asa Citizens Hospital, Japan"},{"name":"Department of Respiratory Internal Medicine, Onomichi General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Onomichi General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mako","family":"Tsuyuki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Internal Medicine, Hiroshima City North Medical Center Asa Citizens Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kakumoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Internal Medicine, Hiroshima City North Medical Center Asa Citizens Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Internal Medicine, Hiroshima City North Medical Center Asa Citizens Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hamai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Internal Medicine, Hiroshima City North Medical Center Asa Citizens Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ramos-Casals M, Brito-Zer\u00f3n P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol 17: 315-332, 2021.","DOI":"10.1038\/s41584-021-00608-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kharouf F, Kenig A, Bohbot E, Rubin L, Peleg H, Shamriz O. Increase rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single centre experience. Clin Exp Rheumatol 41: 316-321, 2023.","DOI":"10.55563\/clinexprheumatol\/970881"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wang G, Wang Q, Wang Y, et al. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol 12: 791348, 2021.","DOI":"10.3389\/fimmu.2021.791348"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76: 1955-1964, 2017.","DOI":"10.1136\/annrheumdis-2017-212786"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med 201: 1380-1388, 2020.","DOI":"10.1164\/rccm.202002-0445OC"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507-513, 2020.","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hannah JR, Law HE, Gordon T, et al. A systematic review and metaanalysis of predictors of mortality in idiopathic inflammatory myopathy-associated interstitial lung disease. J Rheumatol 50: 373-383, 2023.","DOI":"10.3899\/jrheum.220383"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72: 488-498, 2020.","DOI":"10.1002\/art.41105"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gonzalez D, Gupta L, Murthy V, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. Rheumatol Int 42: 1629-1641, 2022.","DOI":"10.1007\/s00296-022-05149-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int 41: 1021-1036, 2021.","DOI":"10.1007\/s00296-021-04819-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Giannini M, Ohana M, Nespola B, et al. Similarities between COVID-19 and aniti-MDA5 syndrome: what can we learn for better care? Eur Respir J 56: 2001618, 2020.","DOI":"10.1183\/13993003.01618-2020"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. David P, Sinha S, Iqbal K, et al. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). EBiomedicine 104: 105136, 2024.","DOI":"10.1016\/j.ebiom.2024.105136"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 78: e250-e349, 2024.","DOI":"10.1093\/cid\/ciac724"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Irie Y, Wakabayashi H, Matuzawa Y, Hiruta N, Kaneko K. A case of anti-synthetase syndrome with anti-glycyl tRNA synthetases antibody developed after COVID-19. Cureus 16: e58004, 2024.","DOI":"10.7759\/cureus.58004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Haselwanter P, Bal C, Gompelmann D, et al. Sustained treatment response after intravenous cyclophosphamide in a patient with therapy-resistant COVID-19 acute respiratory distress syndrome: a case report. J Clin Med 12: 5506, 2023.","DOI":"10.3390\/jcm12175506"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Brummaier T, Pohanka E, Studnicka-Benke A, Pieringer H. Using cyclophosphamide in inflammatory rheumatic diseases. Eur J Intern Med 24: 590-596, 2013.","DOI":"10.1016\/j.ejim.2013.02.008"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Teles KA, Medeiros-Souza P, Lima FAC, Ara\u00fajo BG, Lima RAC. Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Rev Bras Reumatol Engl Ed 57: 596-604, 2017.","DOI":"10.1016\/j.rbre.2016.09.008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Qian J, Li R, Chen Z, Cao Z, Lu L, Fu Q. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front Immunol 14: 1151695, 2023.","DOI":"10.3389\/fimmu.2023.1151695"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sato-Okabayashi Y, Isoda K, Heissig B, et al. Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis. Int J Cardiol Heart Vasc 28: 100529, 2020.","DOI":"10.1016\/j.ijcha.2020.100529"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Keshtkarjahromi M, Chhetri S, Balagani A, et al. Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection. BMC Rheumatol 5: 59, 2021.","DOI":"10.1186\/s41927-021-00225-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tonutti A, Motta F, Ceribelli A, et al. Anti-MDA5 antibody linking COVID-19, type I interferon, and autoimmunity: a case report and systematic literature review. Front Immunol 13: 937667, 2022.","DOI":"10.3389\/fimmu.2022.937667"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Anderle K, Machold K, Kiener HP, et al. COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report. BMC Rheumatol 6: 42, 2022.","DOI":"10.1186\/s41927-022-00271-1"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/14\/65_5163-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:26:06Z","timestamp":1784345166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/14\/65_5163-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":22,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5163-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"5163-24"}}